Cynaroside pretreatment significantly reduced the apoptotic rate by enhancing the endogenous anti-oxidative activity of superoxide dismutase, glutathione peroxidase, and catalase, thereby inhibiting intracellular reactive oxygen species (ROS) generation. Moreover, cynaroside moderated H(2) O(2) -induced disruption of mitochondrial membrane potential, increased the expression of anti-apoptotic protein Bcl-2 while decreased the expression of pro-apoptotic protein Bax, and thereby inhibited the release of apoptogenic factors (cytochrome c and smac/Diablo) from mitochondria in H9c2 cells. Cynaroside prevents H(2) O(2) -induced apoptosis in H9c2 cell by reducing the endogenous production of ROS, maintaining mitochondrial function, and modulating the JNK and P53 pathways.
|Solubility (25°C)||Soluble in warmed water|
|Storage||2-8°C, dry, protect from light, sealed|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Sun X, et al. J Cell Biochem. Protective effects of cynaroside against H₂O₂-induced apoptosis in H9c2 cardiomyoblasts.
|Related Akt Products|
Recilisib (ON 01210) sodium is a radioprotectant, which can activate AKT, PI3K activities in cells.
ZINC00640089 is a specific Lipocalin-2 (LCN2) inhibitor. ZINC00640089 inhibits cell proliferation, cell viability and reduces AKT phosphorylation levels in SUM149 cells.
TAS-117 is a potent, selective, orally active allosteric Akt inhibitor (IC50 of 4.8, 1.6 and 44 nM for Akt1, 2 and 3, respectively).TAS-117 stimulates anti-myeloma activity and enhances lethal endoplasmic reticulum stress induced by proteasome inhibition.TAS-117 induces apoptosis and autophagy. autophagy).
NTQ1062 is an oral ATP-competitive Akt inhibitor being developed for cancer.
Borussertib is a covalent-allosteric inhibitor of protein kinase Akt with an IC50 of 0.8 nM and a Ki of 2.2 nM for WT Akt.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.